Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. It operates in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside, in a Phase 2 trial for rare kidney diseases including Alport syndrome, cystic fibrosis, and nephropathic cystinosis, each with nonsense mutations; it is also in preclinical development for autosomal dominant polycystic kidney disease with nonsense mutations. Eloxx collaborates with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for rare skin diseases such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Incorporated in 1999, the company is based in Arlington, Massachusetts.